PANDinactive

Pandion Therapeutics, Inc.

Healthcare·Immunology·Phase 1
ImmunologyGastroenterology

Pandion Therapeutics, Inc. (PAND): 4 pipeline candidates. Updated within the last hour.

7.1/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

0% dilution

Pipeline Maturity4.0

Lead: Phase 1

Pipeline Breadth7.2

4 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Pandion Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$220.4M

Quarterly Burn

—

Runway

—

Revenue

—

Pipeline (4 candidates)

DrugPhase
pt001Preclinical
pt002Preclinical
pt101Phase 1
pt627Preclinical

Frequently asked questions

How many drug candidates are in Pandion Therapeutics, Inc.'s pipeline?

Pandion Therapeutics, Inc. (PAND) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Pandion Therapeutics, Inc.'s lead drug candidate?

Pandion Therapeutics, Inc.'s most advanced tracked candidate is pt001 (Preclinical) for autoimmune diseases of the gastrointestinal tract.

Get the full picture on Pandion Therapeutics, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar